Improving Outcomes Through Proactive Monitoring of Transplant PatientsPremiere Date: Thursday, December 15, 2016
This activity offers CE credit for:%>
- Physicians (CME)
- Nurses (CNE)
- Social Workers (NASW)
- Pharmacists (ACPE)
All other clinicians will receive a Certificate of Attendance stating this activity was certified for AMA PRA Category 1 Credit™
Credit Expiration Date:
Friday, December 15, 2017
Note: Credit Is No Longer Available
|Lewis W. Teperman, MD FACS
Vice Chairman of Surgery
Director of Transplantation
Director, Northwell Health System Transplant Center
Hofstra University Medical School
|Vinay Nair, DO
Medical Director, Kidney and Pancreas Transplantation
Recanati Miller Transplant Institute
Fellowship Director, Transplant Nephrology
Associate Professor of Medicine
Division of Nephrology
Icahn School of Medicine at Mount Sinai
New York, NY
|Pamela E. Hill, ANP-BC, CCTC
New York, NY
The current goal of transplant medicine and immunology is to develop strategies to extend the life and functionality of every allograft. While outcomes of renal and liver transplantation have improved, allograft loss remains a substantial problem associated with increased morbidity, mortality, and costs.1 Identifying the pathologic pathways responsible for allograft loss and developing targeted therapeutic interventions are currently some of the biggest challenges in transplant medicine. Education to clinicians about the various factors that can result in allograft loss and optimal treatment can improve the quality of life of transplant patients.
Involving the patient as an active participant in treatment is essential to medication adherence and monitoring. To best represent the challenges patients face in their transplant journey, audio responses from interviews with patients who have received a transplant will be at the center of the discussion in this CME Outfitters Live and On Demand. Their voice will complement the expert faculty discussion of the latest evidence on antibody-mediated complications, regular monitoring strategies to optimize immunosuppression, and engaging patients in discussions to promote adherence and improve outcomes.
Loupy A, Hill GS, Jordan SC. The impact of donor-specific anti-HLA antibodies on late kidney allograft failure. Nat Rev Nephrol. 2012;8(6):348-57. Accessed November 1, 2016.
At the end of this CE activity, participants should be able to:
- Assess for DSA HLA antibodies to prevent antibody-mediated rejection in kidney and liver transplants.
- Implement regular monitoring strategies that can optimize appropriate immunosuppressant dosing.
- Engage transplant patients to participate in decisions about their treatment to improve outcomes.
The following learning objectives pertain only to those requesting CNE or CPE credit:
- Explain how to assess for DSA HLA antibodies to prevent antibody-mediated rejection in kidney and liver transplants.
- Identify regular monitoring strategies that can optimize appropriate immunosuppression while managing side effects in transplant patients.
- Describe ways to engage transplant patients to become participants in their treatment to promote adherence to medications and improve outcomes.
Supported by educational grants from Astellas and Novartis Pharmaceuticals Corporation
This educational activity is supported by an independent medical education grant from Shire.
Transplant medicine and immunology specialists, physician assistants, nurse practitioners, nurses, pharmacists, and other healthcare professionals with an interest in transplant medicine.
CME Credit (Physicians):
CME Outfitters, LLC, is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
CME Outfitters, LLC, designates this live activity for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
CNE Credit (Nurses):
Provider approved by the California Board of Registered Nursing, Provider Number CEP 15510, for 1.5 contact hours
Note to Nurse Practitioners and Clinical Nurse Specialists: the content of this activity pertains to pharmacology. Earn up to 1.5 contact hours of pharmacotherapeutic contact hours.
NASW Credit (Social Workers):
This program is Approved by the National Association of Social Workers (Approval # 886407722-3928) for 1.5 continuing education contact hours.
CPE Credit (Pharmacists):
CME Outfitters, LLC, is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. 1.5 contact hours (0.15 CEUs)
Universal Activity Number:
0376-0000-16-030-L01-P (live program)
0376-0000-16-030-H01-P (enduring program)
It is the policy of CME Outfitters, LLC, to ensure independence, balance, objectivity, and scientific rigor and integrity in all of their CME/CE activities. Faculty must disclose to the participants any relationships with commercial companies whose products or devices may be mentioned in faculty presentations, or with the commercial supporter of this CME/CE activity. CME Outfitters, LLC, has evaluated, identified, and attempted to resolve any potential conflicts of interest through a rigorous content validation procedure, use of evidence-based data/research, and a multidisciplinary peer review process. The following information is for participant information only. It is not assumed that these relationships will have a negative impact on the presentations.
Pamela E. Hill, ANP-BC, CCTC has no disclosures to report.
Vinay Nair, MD has no disclosures to report.
Lewis W. Teperman, MD FACS has no disclosures to report.
Disclosures were obtained from the CME Outfitters, LLC staff: Nothing to Disclose
Jeffrey Helfand, DO, MS (peer reviewer) has no disclosures to report.
Robert Kennedy (planning committee) has no disclosures to report.
Sharon Tordoff, CCHP (planning committee) has no disclosures to report.
Unlabeled Use Disclosure
Faculty of this CE activity may include discussions of products or devices that are not currently labeled for use by the FDA. The faculty have been informed of their responsibility to disclose to the audience if they will be discussing off-label or investigational uses (any uses not approved by the FDA) of products or devices.
Questions about this activity? Call us at 877.CME.PROS (877.263.7767).